Amandeep Singh

Amandeep Singh

Auto-generated profile, based on publicly available information

Amandeep Singh

Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
ASAmandeep Singh
Amandeep Singh
ADAmaninder S. Dhaliwal
Amaninder S. Dhaliwal
SSShailainder Singh
Shailainder Singh
AKAtul Kumar
Atul Kumar
RLRocio Lopez
Rocio Lopez
NANaim Alkhouri
Naim Alkhouri

11 March 2020 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
ASAmandeep Singh
Amandeep Singh
FGFalgun Gosai
Falgun Gosai
MSMohamed T. Siddiqui
Mohamed T. Siddiqui
MGMohit Gupta
Mohit Gupta
RLRocio Lopez
Rocio Lopez
NANaim Alkhouri
Naim Alkhouri
Background: Recent guidelines have recommended screening for nonalcoholic fatty liver disease (NAFLD) and case finding of advanced disease with fibrosis in patients with type-2 diabetes (T2D). The aim of this study is to assess the accuracy of commonly used noninvasive scores to predict the presence of advanced fibrosis (AF) in a large cohort of diabetics in real-life settings. Patients and Methods: Using International Classification of Diseases, Ninth Revision (ICD-9) codes, all patients with the diagnosis of T2D who had a liver biopsy for suspected NAFLD between January 2000 and December 2015, were identified and analyzed. Patients with secondary causes of hepatic steatosis were excluded. AST/ALT ratio, aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) index, and Nonalcoholic fatty liver disease Fibrosis Score (NFS) were calculated to predict advanced disease. Sensitivity, specificity, and area under the receiver operator curve were calculated and compared with liver biopsies to predict the overall accuracy of each score. Results: A total of 1319 patients with T2D underwent liver biopsy for suspected NAFLD. After exclusions, 1,157 subjects were included in the final analysis. Our cohort consisted of 64.6% females and 88.4% were whites. Overall, 85% of the population was overweight or obese (body mass index>25 kg/m2). Liver biopsy showed 31.7% with AF [Nonalcoholic Steatohepatitis Clinical Research Network (NASH-CRN) stage 3 to 4]. In comparison to liver biopsy, for the diagnosis of AF, AST/ALT>1.4, APRI>1.5, FIB-4>2.67, and NFS>0.676 had reasonable specificities of 84.2%, 97.4%, 69.9%, and 93% but poor sensitivities of 27.4%, 16.5%, 6.7%, and 44.1%, respectively. Even at lower cutoff values of AST/ALT≥1, APRI≥1, and FIB-4≥1.45 sensitivities remained low at 60.7%, 27.9%, and 72.6%, respectively, except for NFS ≥−1.455 with sensitivity of 94.6%, but at this cutoff, its specificity decreased to 16.9%. The area under the receiver operator curve to detect AF was 0.62, 0.74, 0.77, and 0.72, respectively. Conclusions: In this large cohort of adult patients with T2D and NAFLD, commonly used fibrosis scores had reasonable specificity, but poor sensitivity for detecting AF in diabetics. The development of reliable biomarkers for NAFLD/NASH in diabetics is urgently needed.

23 June 2020 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
RGRajat Garg
Rajat Garg
BMBabu P. Mohan
Babu P. Mohan
SPSuresh Ponnada
Suresh Ponnada
ASAmandeep Singh
Amandeep Singh
AAAli Aminian
Ali Aminian
BCBenjamin Click
Benjamin Click

31 January 2019 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
ASAmandeep Singh
Amandeep Singh
FKFreeha Khan
Freeha Khan
RLRocio Lopez
Rocio Lopez
BSBo Shen
Bo Shen
JPJessica Philpott
Jessica Philpott
Chronic antibiotic-refractory pouchitis (CARP) is a complication of ileal pouch-anal anastomosis (IPAA), which poses a therapeutic challenge. Vedolizumab, a gut-selective monoclonal antibody to the α4β7 of integrin, has been used in such patients, but data on its efficacy are limited. Our aim was to assess the efficacy and safety of vedolizumab as induction therapy in CARP patients. In this single-center, historic cohort, patients with CARP who received vedolizumab between January 2015 to June 2017 were identified and analysed. Patients were included if they had active pouchitis with a total of modified pouch disease activity index (mPDAI) score ≥5 or if unavailable clinician diagnosis of active pouchitis. Pre-treatment and at 3-month post-therapy pouchoscopy and clinical visits were used to calculate mPDAI. A total of 19 patients were included in the study. The mean age was 26.7 ± 12.8 years, with 10 (53%) males. Nine (47%) patients had been treated with anti-tumor necrosis factor (TNF) agents before colectomy and 10 (53%) had anti-TNFs after colectomy and IPAA. Six (32%) patients had improvement in the mPDAI symptom subscores (P = 0.031) and 14 (74%) had improvement in both endoscopic and total mPDAI scores with a median change of –2 units (both P = 0.031). Adverse events were noted only in two (11%) patients and four (21%) required surgery for CARP. Our study suggests that vedolizumab has efficacy and can be safely used for CARP patients. Larger studies with a higher number of patients are required to confirm these findings.

4 July 2022 in Annals of Medicine
Verified
Journal Article
Open access
ASAmandeep Singh
Amandeep Singh
MAManik Aggarwal
Manik Aggarwal
RGRajat Garg
Rajat Garg
TSTyler Stevens
Tyler Stevens
PCPrabhleen Chahal
Prabhleen Chahal
Pancreatitis is the leading gastrointestinal cause of hospitalizations. There are multiple short- and long-term complications associated with pancreatitis. Post-pancreatitis diabetes mellitus (PPDM) is one of the less explored complications of pancreatitis. Nonetheless, it has attracted considerable attention during the last decade. PPDM is now the second most common cause of new-onset diabetes mellitus (DM) in adults after type II DM surpassing type 1 DM. However, there exists a knowledge gap amongst practitioners regarding diagnosis, complications, and management of PPDM. In this narrative, we aim to provide a brief review regarding risks, diagnosis and management of PPDM with a special focus on dietary and lifestyle management strategies.

1 December 2021 in Pancreatology
Verified
Journal Article
Closed access
RGRajat Garg
Rajat Garg
SGShradha Gupta
Shradha Gupta
ASAmandeep Singh
Amandeep Singh
MSMarian T. Simonson
Marian T. Simonson
TRTarun Rustagi
Tarun Rustagi
PCPrabhleen Chahal
Prabhleen Chahal